KE3884A - Process for the production of human mono-clonal antibodies - Google Patents

Process for the production of human mono-clonal antibodies

Info

Publication number
KE3884A
KE3884A KE3884A KE388489A KE3884A KE 3884 A KE3884 A KE 3884A KE 3884 A KE3884 A KE 3884A KE 388489 A KE388489 A KE 388489A KE 3884 A KE3884 A KE 3884A
Authority
KE
Kenya
Prior art keywords
production
clonal antibodies
human mono
mono
human
Prior art date
Application number
KE3884A
Other languages
English (en)
Inventor
Lars Oestberg Gunnar
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Publication of KE3884A publication Critical patent/KE3884A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/166—Animal cells resulting from interspecies fusion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KE3884A 1982-01-22 1989-05-16 Process for the production of human mono-clonal antibodies KE3884A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH409/82A CH652145A5 (de) 1982-01-22 1982-01-22 Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.

Publications (1)

Publication Number Publication Date
KE3884A true KE3884A (en) 1989-08-11

Family

ID=4186382

Family Applications (1)

Application Number Title Priority Date Filing Date
KE3884A KE3884A (en) 1982-01-22 1989-05-16 Process for the production of human mono-clonal antibodies

Country Status (17)

Country Link
US (1) US4634664A (cs)
JP (3) JPS58128323A (cs)
AT (1) AT388932B (cs)
CH (1) CH652145A5 (cs)
CY (1) CY1488A (cs)
DE (1) DE3301249A1 (cs)
DK (1) DK23183A (cs)
FI (1) FI83538C (cs)
FR (1) FR2522679B1 (cs)
GB (1) GB2113715B (cs)
HK (1) HK52589A (cs)
IL (1) IL67721A (cs)
IT (1) IT1160468B (cs)
KE (1) KE3884A (cs)
MY (1) MY8700169A (cs)
SE (1) SE502344C2 (cs)
SG (1) SG28189G (cs)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4613576A (en) * 1983-03-09 1986-09-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cancer cells
US4634666A (en) * 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
EP0148644A3 (en) * 1984-01-06 1987-06-03 The Board Of Trustees Of The Leland Stanford Junior University A novel fusion partner and its products
US4764465A (en) * 1984-04-26 1988-08-16 Cetus Corporation Human monoclonal antibody against group A red blood cells
WO1986002092A1 (en) * 1984-09-28 1986-04-10 Teijin Limited Mouse human hybridoma producing antivirus human antibody, process for its preparation, and antivirus human monoclonal antibody
JPS6187630A (ja) * 1984-10-08 1986-05-06 Teijin Ltd 単純ヘルペスウイルスに対するヒトモノクロ−ナル抗体及びその製造法
US4693975A (en) * 1984-11-20 1987-09-15 The Wistar Institute Human hybridroma fusion partner for production of human monoclonal antibodies
JPS61155398A (ja) * 1984-12-28 1986-07-15 Teijin Ltd 抗緑膿菌ヒトモノクロ−ナル抗体及びその製造法並びにそれを有効成分とする治療剤
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
USH1198H (en) 1985-04-26 1993-06-01 Cetus Corporation Pseudomonas aeruginosa type-specific human monoclonal antibodies, their preparation and use
CH670098B (cs) * 1985-05-23 1989-05-12
JPH0720885B2 (ja) * 1985-09-27 1995-03-08 帝人株式会社 単純ヘルペスウイルス感染症の予防又は治療剤
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
AU613310B2 (en) * 1986-04-01 1991-08-01 Genelabs Incorporated Immortalized virus-specific tissue cells
WO1987005929A1 (en) * 1986-04-01 1987-10-08 Genelabs Incorporated Immortalized cells which produce tissue-specific products
US5565354A (en) * 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
US5646041A (en) * 1987-02-12 1997-07-08 Harfeldt; Elisabeth Monoclonal antibody to herpes simplex virus and cell line producing same
US5001065A (en) * 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
JPH01101896A (ja) * 1987-10-14 1989-04-19 Teijin Ltd カンジダに対するヒト・モノクローナル抗体とその製造法
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
IT1226477B (it) * 1988-07-04 1991-01-16 Genetik Mab S R L Linee cellulari n omas quale un mezzo per immortalare cellule produttrici di sostanze di qualunque specie animale.
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2535455B2 (ja) * 1991-02-07 1996-09-18 帝人株式会社 サイトメガロウイルスに対するヒト・モノクロ―ナル抗体を産生するハイブリド―マ
IE922287A1 (en) * 1991-07-15 1993-01-27 Wellcome Found Production of antibodies
JPH05276984A (ja) * 1991-09-05 1993-10-26 Teijin Ltd カンジダに対するヒト・モノクローナル抗体を産生するハイブリドーマ
JPH05260961A (ja) * 1992-05-21 1993-10-12 Teijin Ltd サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ
PL302438A1 (en) * 1992-06-26 1994-07-25 Aetsrn Human anti-rh(d) monoclonal antibodies and cellular lines producing them
EP0583980A1 (en) * 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
FI952171L (fi) * 1992-11-06 1995-07-05 Sandoz Ltd Hepatiitti B-pinta-antigeeneille aktiivisten ihmisen monoklonaalisten vasta-aineiden tuotto
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
AU737406B2 (en) 1997-02-07 2001-08-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Activity dependent neurotrophic factor III (ADNF III)
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2001032712A2 (en) * 1999-11-03 2001-05-10 Maxygen, Inc. Antibody diversity generation
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
WO2002086075A2 (en) 2001-04-19 2002-10-31 The Scripps Research Institute Methods and composition for the production of orthoganal trna-aminoacyltrna synthetase pairs
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003030831A2 (en) * 2001-10-11 2003-04-17 Protein Design Labs, Inc. Treatment of prostate cancer by inhibitors of atp synthase
EP1572121B1 (en) 2002-08-01 2012-01-11 The Regents of The University of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
ES2640669T3 (es) 2003-05-19 2017-11-03 Prothena Biosciences Limited Fragmentos truncados de alfa-sinucleína en enfermedad con cuerpos de lewy
EP1633312A4 (en) 2003-06-16 2012-09-26 Medimmune Llc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
US7993872B2 (en) 2003-06-18 2011-08-09 The Scripps Research Institute Unnatural reactive amino acid genetic code additions
EP2902484A1 (en) 2004-05-25 2015-08-05 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
AU2006332045A1 (en) 2005-01-27 2007-08-16 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
NZ555937A (en) 2005-01-27 2009-05-31 Childrens Hosp & Res Ct Oak GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
EP2471552B1 (en) 2005-03-08 2015-05-06 MedImmune, LLC Reassortant influenza viruses
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
DE602006014691D1 (de) * 2005-08-02 2010-07-15 Xbiotech Inc DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2007027906A2 (en) * 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
WO2007117410A2 (en) 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
KR101429254B1 (ko) * 2006-04-13 2014-08-18 가부시키가이샤 이가쿠세이부츠가쿠겐큐쇼 융합 파트너 세포
WO2007127335A2 (en) * 2006-04-27 2007-11-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
PL2109623T3 (pl) * 2006-05-22 2012-03-30 Xbiotech Inc Leczenie nowotworu przeciwciałami przeciw il-1
DK2046809T3 (en) 2006-07-19 2017-03-13 Univ Pennsylvania WSX-1 / IL-27 AS A TARGET OBJECTIVE FOR ANTI-INFLAMMATORY REACTIONS
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US8080645B2 (en) * 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
WO2008083169A2 (en) * 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
US7989173B2 (en) * 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
WO2008083239A2 (en) * 2006-12-27 2008-07-10 The Johns Hopkins University Compositions and methods for stimulating an immune response
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
HUE043966T2 (hu) 2007-02-23 2019-09-30 Prothena Biosciences Ltd Szinukleinopátiás és amiloidogén betegség megelõzése és kezelése
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1975184A3 (en) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serine or threonine phosphorylation sites
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
EP2145902A3 (en) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP3293269A1 (en) 2007-08-03 2018-03-14 MUSC Foundation For Research Development Human monoclonal antibodies and methods for producing the same
US9624309B2 (en) 2007-08-15 2017-04-18 Bayer Intellectual Property Gmbh Monospecific and multispecific antibodies and method of use
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
CA2697373C (en) 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP2535428B1 (en) 2007-10-01 2015-09-09 Longhorn Vaccines and Diagnostics, LLC Biological specimen collection and transport system and methods of use
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
US20110020941A1 (en) 2007-10-05 2011-01-27 National Institute for Bioprocessing Research and Training Limited Glycosylation markers for pancreatitis, sepsis and pancreatic cancer
EP2062920A3 (en) 2007-11-21 2009-06-17 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
US20090169549A1 (en) * 2007-12-19 2009-07-02 The Board Of Regents Of The University Of Texas System Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP2274437B1 (en) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
ES2576681T3 (es) * 2008-05-30 2016-07-08 Xbiotech, Inc Anticuerpos IL-1 alfa
US20110129816A1 (en) * 2008-06-06 2011-06-02 National University Corporation University Of Toyama Device for detection of influenza virus
RU2523587C2 (ru) 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
EP2326347A4 (en) * 2008-09-12 2013-03-06 Xbiotech Inc TARGETING ILLNESSING MONOCYTES
WO2010085590A1 (en) 2009-01-23 2010-07-29 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
CA2752205A1 (en) 2009-02-12 2010-08-19 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
EP2473521A2 (en) 2009-08-31 2012-07-11 Amplimmune, Inc. B7-h4 fusion proteins and methods of use thereof
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
ES2703774T3 (es) 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
ES2622482T3 (es) 2010-08-23 2017-07-06 Xbiotech, Inc Tratamiento de enfermedades neoplásicas
PL2648752T3 (pl) 2010-12-06 2017-07-31 Seattle Genetics, Inc. Humanizowane przeciwciała przeciwko liv-1 oraz ich zastosowanie do leczenia raka
JP6062918B2 (ja) 2011-04-01 2017-01-18 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 皮膚科的病理の治療
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN108404127A (zh) 2011-09-23 2018-08-17 埃克斯生物科技公司 恶病质治疗
EP3494989B1 (en) 2012-01-26 2025-07-16 Longhorn Vaccines and Diagnostics, LLC Composite antigenic sequences and vaccines
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
MX376241B (es) 2012-10-04 2025-03-06 Xbiotech Inc Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones.
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
SG10201707855YA (en) 2013-03-13 2017-10-30 Prothena Biosciences Ltd Tau immunotherapy
US9803017B2 (en) 2013-07-05 2017-10-31 University Of Washington Through Its Center For Commercialization Soluble MIC neutralizing monoclonal antibody for treating cancer
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
PL3041513T3 (pl) 2013-09-08 2021-01-25 Kodiak Sciences Inc. Obojnaczojonowe polimerowe koniugaty czynnika viii
WO2015136471A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
DK3116911T3 (da) 2014-03-12 2019-09-30 Prothena Biosciences Ltd Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
KR20160131073A (ko) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Lg4-5에 대해 특이적인 항-라미닌4 항체
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
KR102210104B1 (ko) 2014-10-17 2021-02-01 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718122B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
JP2018518461A (ja) 2015-04-29 2018-07-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 進行性骨化性線維異形成症の治療
US9976136B2 (en) 2015-05-14 2018-05-22 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
JP2018530540A (ja) 2015-09-16 2018-10-18 プロセナ バイオサイエンシーズ リミテッド 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗ｍｃａｍ抗体の使用
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
KR102355950B1 (ko) 2016-03-04 2022-01-26 제이엔 바이오사이언시즈 엘엘씨 Tigit에 대한 항체
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
KR102533675B1 (ko) 2016-05-02 2023-05-22 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
PT3482210T (pt) 2016-07-06 2021-07-28 Prothena Biosciences Ltd Ensaio para detetar alfa-sinucleína total e fosforilada s129
CA3053231A1 (en) 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
US11584790B2 (en) 2017-04-14 2023-02-21 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
MX2019013045A (es) 2017-05-02 2020-02-12 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
WO2018222675A1 (en) 2017-05-30 2018-12-06 The Board Of Regents Of The University Of Oklahoma Anti-doublecortin-like kinase 1 antibodies and methods of use
US11464845B2 (en) 2017-07-21 2022-10-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neisseria meningitidis immunogenic compositions
JP7292569B2 (ja) 2017-10-06 2023-06-19 ノボ ノルディスク エー／エス トランスサイレチンを検出する方法
SG11202002590VA (en) 2017-11-02 2020-04-29 Bayer Ag Bispecific antibodies binding alk-1 and bmpr-2
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
US20220023348A1 (en) 2018-11-28 2022-01-27 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
TW202045206A (zh) 2019-02-27 2020-12-16 美商健生生物科技公司 抗體調配物
CU20210073A7 (es) 2019-03-03 2022-04-07 Prothena Biosciences Ltd Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2022008494A (es) 2020-01-08 2022-10-10 Regeneron Pharma Tratamiento de la fibrodisplasia osificante progresiva.
WO2021211924A1 (en) 2020-04-16 2021-10-21 Janssen Biotech, Inc. Treatment of atopic dermatitis
AU2021284273A1 (en) 2020-06-02 2022-12-15 Arcus Biosciences, Inc. Antibodies to TIGIT
WO2021263279A1 (en) 2020-06-24 2021-12-30 Prothena Biosciences Limited Antibodies recognizing sortilin
US12409214B2 (en) 2020-10-20 2025-09-09 Longhorn Vaccines And Diagnostics, Llc Immunogenic antigens
JP2024503908A (ja) 2021-01-22 2024-01-29 バイエル アクチェンゲゼルシャフト Ｌｒｒｃ１５抗体およびそのコンジュゲート
WO2022265912A1 (en) 2021-06-16 2022-12-22 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope
WO2025006737A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
EP4527851A1 (en) 2023-09-22 2025-03-26 Bayer Aktiengesellschaft Bispecific antibodies binding ltbr and lrrc15

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757169A1 (de) * 1977-12-22 1979-07-05 Hoechst Ag Verfahren zur gewinnung insulin produzierender tierischer zellen
ZA806506B (en) * 1979-11-01 1981-09-30 Bio Response Inc A method for production of monoclonal antibodies
DE3167442D1 (en) * 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
GB2079313A (en) * 1980-07-07 1982-01-20 Nat Res Dev Improvements in or relating to rat myeloma cell lines
JPS57502090A (cs) * 1980-07-18 1982-11-25
JPS586475B2 (ja) * 1980-08-23 1983-02-04 株式会社 林原生物化学研究所 ヒト絨毛性性腺刺激ホルモンの製造方法
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
JPS585671B2 (ja) * 1980-08-27 1983-02-01 株式会社 林原生物化学研究所 ヒト卵胞刺激ホルモンの製造方法
JPS5743696A (en) * 1980-08-27 1982-03-11 Hayashibara Biochem Lab Inc Preparation of human luteinizing hormone
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4529694A (en) * 1982-04-16 1985-07-16 The Children's Medical Center Corporation Cell fusion

Also Published As

Publication number Publication date
ATA19583A (de) 1989-02-15
JPH0789909B2 (ja) 1995-10-04
GB2113715B (en) 1986-06-04
CY1488A (en) 1989-12-08
HK52589A (en) 1989-07-07
IT8319234A0 (it) 1983-01-21
JPH0471520B2 (cs) 1992-11-13
IT1160468B (it) 1987-03-11
MY8700169A (en) 1987-12-31
DE3301249C2 (cs) 1990-04-05
FR2522679B1 (fr) 1986-05-09
JPH0690753A (ja) 1994-04-05
JPH03236794A (ja) 1991-10-22
DE3301249A1 (de) 1983-09-22
IL67721A (en) 1986-04-29
GB8301384D0 (en) 1983-02-23
SE8300290L (sv) 1983-07-23
SG28189G (en) 1989-08-11
FI83538C (fi) 1991-07-25
AT388932B (de) 1989-09-25
DK23183A (da) 1983-07-23
FI830190A0 (fi) 1983-01-20
FI830190L (fi) 1983-07-23
CH652145A5 (de) 1985-10-31
FR2522679A1 (fr) 1983-09-09
SE8300290D0 (sv) 1983-01-20
IL67721A0 (en) 1983-05-15
JPH0365148B2 (cs) 1991-10-09
SE502344C2 (sv) 1995-10-09
FI83538B (fi) 1991-04-15
US4634664A (en) 1987-01-06
DK23183D0 (da) 1983-01-20
JPS58128323A (ja) 1983-07-30
GB2113715A (en) 1983-08-10

Similar Documents

Publication Publication Date Title
GB2113715B (en) Process for the production of human mono-clonal antibodies
PT76830A (en) Process for the preparation of 1h-indole-methanesulphonamides
GB2096146B (en) Process for the production of human antibodies
DE3368047D1 (en) Process for the preparation of p-nitrosodiphenylamine
CY1470A (en) Process for the preparation of phenylalkylaminoethylsalicylamide
PH18877A (en) Process for the manufacture of 1-sulfo-2-oxoaze-tidine derivatives
ZA836193B (en) Process for the preparation of n-allyl-o-alkyl thioncarbamates
DE3160090D1 (en) Process for the preparation of 2-mercaptobenzthiazoles
DE3360101D1 (en) Process for the manufacture of reactive-dye preparations
DE3372479D1 (en) Process for the preparation of 4-chloro-2-nitrobenzonitrile
DE3160603D1 (en) Process for the preparation of fluorobenzonitriles
PT76175B (en) Process for the preparation of benzothienyl-dialkylallylamines
DE3367912D1 (en) Process for the preparation of n-allyl-o-alkyl-thioncarbamates
DE3362429D1 (en) Process for the preparation of thiadiazoloxyacetamides
ZM8083A1 (en) Process for the preparation of opticaly
DE3369121D1 (en) Process for the preparation of disulphides
DE3361356D1 (en) Process for the preparation of 3-acylaminoanilines
DE3360384D1 (en) Process for the preparation of 1-hydroxyketones
GB2118173B (en) Process for the manufacture of nitrophenetoles
DE3365382D1 (en) Process for the preparation of 2-chlorobenzoxazols
DE3160225D1 (en) Process for the preparation of 1-phenyl-3-carbamoyl-pyrazol-5-ones
DE3160389D1 (en) Process for the preparation of 2-chloro-benzothiazoles
PT77495A (en) Process for the manufacture of dibenzazepine-carboxamides
GB2092156B (en) Process for the production of human tyroid-stimulating hormone
GB2132206B (en) Improved process for the production of protein fibres